Neulasta and Mesenteric vascular insufficiency - a phase IV clinical study of FDA data

Summary:

Mesenteric vascular insufficiency is reported as a side effect among people who take Neulasta (pegfilgrastim), especially for people who are female, 30-39 old, also take Aranesp, and have Sleep apnea syndrome.

The phase IV clinical study analyzes which people have Mesenteric vascular insufficiency when taking Neulasta. It is created by eHealthMe based on reports of 92,148 people who have side effects when taking Neulasta from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Mesenteric vascular insufficiency?

Mesenteric vascular insufficiency (insufficient vascular supply to mesenteric) is found to be associated with 59 drugs and 97 conditions by eHealthMe. Check the latest studies of Mesenteric vascular insufficiency.

On Aug, 08, 2026

92,148 people reported to have side effects when taking Neulasta.
Among them, 26 people (0.03%) have Mesenteric vascular insufficiency.

Could Neulasta cause Mesenteric vascular insufficiency?

Among these 26 people:

What is the gender of people who have Mesenteric vascular insufficiency when taking Neulasta? *

female: 100 %
male: 0.0 %

What is the age of people who have Mesenteric vascular insufficiency when taking Neulasta? *

What are other drugs people take besides Neulasta? *

What are other side effects people have besides Mesenteric vascular insufficiency? *

Weight Increased: 26 people, 100.00%
Pain In Jaw: 26 people, 100.00%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 26 people, 100.00%
Neuropathy Peripheral (surface nerve damage): 26 people, 100.00%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 26 people, 100.00%
Muscle Spasms (muscle contraction): 26 people, 100.00%
Memory Loss: 26 people, 100.00%
Malaise (a feeling of general discomfort or uneasiness): 26 people, 100.00%
Injury: 26 people, 100.00%
Infection: 26 people, 100.00%

What are the existing conditions these people have? *

Sleep Apnea Syndrome: 23 people, 88.46%
Bone Density Decreased: 15 people, 57.69%
Metastases To Bone (cancer spreads to bone): 6 people, 23.08%
Bone Loss: 4 people, 15.38%
Resorption Bone Increased: 1 person, 3.85%
Pain: 1 person, 3.85%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and have Mesenteric vascular insufficiency?

- Check whether Mesenteric vascular insufficiency is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neulasta:

Neulasta (92,286 reports)

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mesenteric vascular insufficiency:

Mesenteric vascular insufficiency (59 drugs)

Browse all the conditions that are associated with Mesenteric vascular insufficiency:

Mesenteric vascular insufficiency (97 conditions)

Related publications that referenced our studies

Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .
Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim (the active ingredients of Neulasta) and Neulasta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.